We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+6.78%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$150M
AUM Growth
-$10.7M
Cap. Flow
-$11.4M
Cap. Flow %
-7.61%
Top 10 Hldgs %
46.24%
Holding
65
New
12
Increased
10
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.24M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.07M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.58M
4
MGNX icon
MacroGenics
MGNX
+$2.53M
5
NGNE icon
Neurogene
NGNE
+$2.34M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$5.29M
2
ASRT
Assertio
ASRT
+$4.53M
3
GERN icon
Geron
GERN
+$3.87M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.38M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2.91M

Sector Composition

Rank Sector Weight
1 Healthcare 91.89%
2 Miscellaneous 8.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
51
Nektar Therapeutics
NKTR
$2.55B
– –
-3,333
Closed -$688K
PRTA icon
52
Prothena Corp
PRTA
$467M
– –
-14,000
Closed -$576K
SAGE
53
DELISTED
Sage Therapeutics
SAGE
– –
-165,000
Closed -$5.29M
TVTX icon
54
Travere Therapeutics
TVTX
$6.36B
– –
-150,000
Closed -$2.05M
XOMA
55
DELISTED
Xoma
XOMA
– –
-67,500
Closed -$1.04M
ALPN
56
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-25,000
Closed -$417K
NBSE
57
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
– –
-915
Closed -$1.18M
ISEE
58
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-80,000
Closed -$3.38M
CHMA
59
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-20,000
Closed -$183K
AKAO
60
DELISTED
Achaogen Inc
AKAO
– –
-255,000
Closed -$704K
MDVN
61
DELISTED
MEDIVATION, INC.
MDVN
– –
-14,500
Closed -$667K
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2016 Portfolio in Review

As of Q2 2016, Opaleye Management held 65 positions worth $150M, down 6.6% from $160M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Opaleye Management withdrew a net $11.4M in Q2 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was Sage Therapeutics, an estimated $5.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.29M.

  • Opaleye Management's largest Q2 2016 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 200,000 shares worth $3.29M.
  • Opaleye Management added most to Aevi Genomic Medicine Inc in Q2 2016, an estimated $2.06M increase.
  • Opaleye Management's biggest Q2 2016 reduction was Ultragenyx Pharmaceutical, cutting an estimated $2.91M.
  • Opaleye Management fully exited Sage Therapeutics in Q2 2016, selling an estimated $5.29M.
  • Opaleye Management's ten largest holdings make up 46% of its $150M portfolio in Q2 2016.
  • Opaleye Management opened 12 new positions and closed 16 in Q2 2016.
  • Opaleye Management's portfolio value fell 6.6% quarter-over-quarter to $150M.

Based on Opaleye Management's 13F filing for Q2 2016, filed 12 Aug 2016.